BR112021012812A2 - Csf1r inhibitors para uso e tratamento de câncer - Google Patents
Csf1r inhibitors para uso e tratamento de câncerInfo
- Publication number
- BR112021012812A2 BR112021012812A2 BR112021012812A BR112021012812A BR112021012812A2 BR 112021012812 A2 BR112021012812 A2 BR 112021012812A2 BR 112021012812 A BR112021012812 A BR 112021012812A BR 112021012812 A BR112021012812 A BR 112021012812A BR 112021012812 A2 BR112021012812 A2 BR 112021012812A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- csf1r inhibitors
- treatment
- giant cell
- csf1r
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 101150053778 CSF1R gene Proteins 0.000 title 1
- 208000007990 Giant Cell Tumor of Tendon Sheath Diseases 0.000 abstract 2
- 201000008754 Tenosynovial giant cell tumor Diseases 0.000 abstract 2
- 210000004981 tumor-associated macrophage Anatomy 0.000 abstract 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 208000035647 diffuse type tenosynovial giant cell tumor Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000007420 pigmented villonodular synovitis Diseases 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000002336 repolarization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
inibidores csf1r para uso no tratamento do câncer. são descritos neste documento inibidores de csf1r para uso em métodos de tratamento de câncer e outros tumores relacionados à proliferação diminuída, depleção ou repolarização de macrófagos associados a tumor (tams) e tratamento de doenças associadas, incluindo tumor de células gigantes tenossinovial (tgct) e tumor difuso de células gigantes tenossinoviais (dtgct).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862786105P | 2018-12-28 | 2018-12-28 | |
US201962926341P | 2019-10-25 | 2019-10-25 | |
US201962933830P | 2019-11-11 | 2019-11-11 | |
PCT/US2019/068311 WO2020139828A1 (en) | 2018-12-28 | 2019-12-23 | Csf1r inhibitors for use in treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021012812A2 true BR112021012812A2 (pt) | 2021-12-07 |
Family
ID=69191281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021012812A BR112021012812A2 (pt) | 2018-12-28 | 2019-12-23 | Csf1r inhibitors para uso e tratamento de câncer |
Country Status (22)
Country | Link |
---|---|
US (3) | US11103507B2 (pt) |
EP (2) | EP3902547B1 (pt) |
JP (1) | JP2022516090A (pt) |
KR (1) | KR20210119411A (pt) |
CN (1) | CN113453684B (pt) |
AU (1) | AU2019416117B2 (pt) |
BR (1) | BR112021012812A2 (pt) |
CA (1) | CA3124112A1 (pt) |
DK (1) | DK3902547T3 (pt) |
ES (1) | ES2964489T3 (pt) |
FI (1) | FI3902547T3 (pt) |
HR (1) | HRP20231478T1 (pt) |
IL (1) | IL284199A (pt) |
LT (1) | LT3902547T (pt) |
MX (1) | MX2021007927A (pt) |
PL (1) | PL3902547T3 (pt) |
PT (1) | PT3902547T (pt) |
RS (1) | RS64993B1 (pt) |
SG (1) | SG11202105747XA (pt) |
SI (1) | SI3902547T1 (pt) |
TW (1) | TW202041218A (pt) |
WO (1) | WO2020139828A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111818915B (zh) | 2018-01-31 | 2024-05-24 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
WO2020139828A1 (en) * | 2018-12-28 | 2020-07-02 | Deciphera Pharmaceuticals, Llc | Csf1r inhibitors for use in treating cancer |
WO2020231808A1 (en) | 2019-05-10 | 2020-11-19 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
US11530206B2 (en) | 2019-05-10 | 2022-12-20 | Deciphera Pharmaceuticals, Llc | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
CA3143489A1 (en) | 2019-06-17 | 2020-12-24 | Deciphera Pharmaceuticals, Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
AU2020329956B2 (en) | 2019-08-12 | 2023-11-16 | Deciphera Pharmaceuticals, Llc. | Ripretinib for treating gastrointestinal stromal tumors |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
JP2023509628A (ja) | 2019-12-30 | 2023-03-09 | デシフェラ・ファーマシューティカルズ,エルエルシー | 1-(4-ブロモ-5-(1-エチル-7-(メチルアミノ)-2-オキソ-1,2-ジヒドロ-1,6-ナフチリジン-3-イル)-2-フルオロフェニル)-3-フェニル尿素の組成物 |
BR112022013109A2 (pt) | 2019-12-30 | 2022-09-06 | Deciphera Pharmaceuticals Llc | Formulações de inibidor de quinase amorfo e métodos de uso das mesmas |
WO2022063134A1 (zh) * | 2020-09-23 | 2022-03-31 | 中国科学院上海药物研究所 | Csf1r激酶抑制剂及其用途 |
IL302807A (en) | 2020-11-18 | 2023-07-01 | Deciphera Pharmaceuticals Llc | GCN2 and PERK kinase inhibitors and methods of using them |
CN113880812A (zh) * | 2021-11-17 | 2022-01-04 | 上海皓元生物医药科技有限公司 | 一种csf-ir抑制剂的制备方法 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5794047A (en) | 1980-12-01 | 1982-06-11 | Ricoh Co Ltd | Novel disazo compound and preparation of the same |
AU2002312933B2 (en) | 2001-05-29 | 2007-12-06 | Schering Ag | CDK inhibiting pyrimidines, production thereof and their use as medicaments |
DE60233736D1 (de) | 2001-06-22 | 2009-10-29 | Kirin Pharma K K | Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
EP2942349A1 (en) | 2004-12-23 | 2015-11-11 | Deciphera Pharmaceuticals, LLC | Enzyme modulators and treatments |
EP1933832A2 (en) | 2005-06-23 | 2008-06-25 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
WO2008046216A1 (en) | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
WO2008079291A2 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
AU2008242720A1 (en) | 2007-04-20 | 2008-10-30 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
AU2009219376B2 (en) | 2008-02-28 | 2014-09-25 | Merck Patent Gmbh | Protein kinase inhibitors and use thereof |
MX2011004535A (es) | 2008-10-29 | 2011-11-18 | Deciphera Pharmaceuticals Llc | Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas. |
US8569319B2 (en) | 2010-04-29 | 2013-10-29 | Deciphera Pharmaceuticals, LLS | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
CN103068384B (zh) | 2010-04-29 | 2015-03-11 | 德西费拉制药有限责任公司 | 表现出抗癌和抗增生活性的环丙基二甲酰胺以及类似物 |
WO2013078295A2 (en) | 2011-11-22 | 2013-05-30 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
US9187474B2 (en) | 2012-03-07 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US9133183B2 (en) | 2013-03-15 | 2015-09-15 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
US9193719B2 (en) | 2013-03-15 | 2015-11-24 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2014145025A2 (en) * | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
US9012635B2 (en) | 2013-03-15 | 2015-04-21 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
US9309224B2 (en) | 2013-03-15 | 2016-04-12 | Deciphera Pharmaceuticals, Llc. | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2014145028A2 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
CA3065365A1 (en) | 2017-05-30 | 2018-12-06 | Daniel L. Flynn | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha |
JP2021512101A (ja) | 2018-01-31 | 2021-05-13 | デシフェラ・ファーマシューティカルズ,エルエルシー | 肥満細胞症の治療のための併用療法 |
WO2020139828A1 (en) * | 2018-12-28 | 2020-07-02 | Deciphera Pharmaceuticals, Llc | Csf1r inhibitors for use in treating cancer |
WO2020231808A1 (en) | 2019-05-10 | 2020-11-19 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
US11530206B2 (en) | 2019-05-10 | 2022-12-20 | Deciphera Pharmaceuticals, Llc | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
-
2019
- 2019-12-23 WO PCT/US2019/068311 patent/WO2020139828A1/en active Application Filing
- 2019-12-23 CN CN201980092790.1A patent/CN113453684B/zh active Active
- 2019-12-23 ES ES19842712T patent/ES2964489T3/es active Active
- 2019-12-23 LT LTEPPCT/US2019/068311T patent/LT3902547T/lt unknown
- 2019-12-23 KR KR1020217024011A patent/KR20210119411A/ko unknown
- 2019-12-23 EP EP19842712.2A patent/EP3902547B1/en active Active
- 2019-12-23 SI SI201930651T patent/SI3902547T1/sl unknown
- 2019-12-23 PL PL19842712.2T patent/PL3902547T3/pl unknown
- 2019-12-23 SG SG11202105747XA patent/SG11202105747XA/en unknown
- 2019-12-23 EP EP23195809.1A patent/EP4303583A3/en active Pending
- 2019-12-23 PT PT198427122T patent/PT3902547T/pt unknown
- 2019-12-23 RS RS20231149A patent/RS64993B1/sr unknown
- 2019-12-23 BR BR112021012812A patent/BR112021012812A2/pt unknown
- 2019-12-23 JP JP2021537759A patent/JP2022516090A/ja active Pending
- 2019-12-23 FI FIEP19842712.2T patent/FI3902547T3/fi active
- 2019-12-23 CA CA3124112A patent/CA3124112A1/en active Pending
- 2019-12-23 AU AU2019416117A patent/AU2019416117B2/en active Active
- 2019-12-23 US US16/725,282 patent/US11103507B2/en active Active
- 2019-12-23 MX MX2021007927A patent/MX2021007927A/es unknown
- 2019-12-23 DK DK19842712.2T patent/DK3902547T3/da active
- 2019-12-23 HR HRP20231478TT patent/HRP20231478T1/hr unknown
- 2019-12-27 TW TW108148219A patent/TW202041218A/zh unknown
-
2021
- 2021-06-20 IL IL284199A patent/IL284199A/en unknown
- 2021-06-25 US US17/358,137 patent/US11679110B2/en active Active
-
2023
- 2023-04-28 US US18/140,942 patent/US20230414614A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL284199A (en) | 2021-08-31 |
US20200253973A1 (en) | 2020-08-13 |
US11103507B2 (en) | 2021-08-31 |
US11679110B2 (en) | 2023-06-20 |
EP3902547B1 (en) | 2023-09-20 |
AU2019416117B2 (en) | 2024-05-02 |
EP4303583A2 (en) | 2024-01-10 |
JP2022516090A (ja) | 2022-02-24 |
TW202041218A (zh) | 2020-11-16 |
RS64993B1 (sr) | 2024-01-31 |
CN113453684B (zh) | 2024-05-14 |
FI3902547T3 (fi) | 2023-12-05 |
AU2019416117A1 (en) | 2021-06-17 |
ES2964489T3 (es) | 2024-04-08 |
DK3902547T3 (da) | 2023-12-18 |
US20220143018A1 (en) | 2022-05-12 |
EP4303583A3 (en) | 2024-03-27 |
SG11202105747XA (en) | 2021-07-29 |
PT3902547T (pt) | 2023-12-04 |
CN113453684A (zh) | 2021-09-28 |
LT3902547T (lt) | 2024-01-25 |
US20230414614A1 (en) | 2023-12-28 |
CA3124112A1 (en) | 2020-07-02 |
SI3902547T1 (sl) | 2024-02-29 |
EP3902547A1 (en) | 2021-11-03 |
KR20210119411A (ko) | 2021-10-05 |
WO2020139828A1 (en) | 2020-07-02 |
PL3902547T3 (pl) | 2024-02-26 |
MX2021007927A (es) | 2021-10-26 |
HRP20231478T1 (hr) | 2024-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021012812A2 (pt) | Csf1r inhibitors para uso e tratamento de câncer | |
CL2020002914A1 (es) | Métodos y composiciones para tratar el cáncer | |
CY1123297T1 (el) | Anti-bcma αντισωματα, διειδικα μορια συνδεσης αντιγονου που συνδεουν bcma και cd3, και χρησεις αυτων | |
CY1121450T1 (el) | Θεραπεια συνδυασμου για θεραπεια καρκινου | |
BR112017028530A2 (pt) | terapia combinada para tratamento de cânceres hematológicos e tumores sólidos | |
CY1122642T1 (el) | Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου | |
BR112021022812A2 (pt) | Dosagem de inibidor de kras para tratamento de cânceres | |
EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
CY1119799T1 (el) | Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου | |
EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
MX2018010261A (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
MX2015014486A (es) | Marcadores de respuesta de células tumorales a la terapia. | |
CY1123043T1 (el) | Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων | |
NZ728604A (en) | Protein kinase c inhibitors and methods of their use | |
EA201890801A1 (ru) | Способ лечения злокачественной рабдоидной опухоли яичников (mrto)/мелкоклеточного рака яичников гиперкальцемического типа (sccoht) с помощью ингибитора ezh2 | |
EA201891304A1 (ru) | ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ | |
CO2021002024A2 (es) | Compuestos de piridin-2-ona útiles como antagonistas de smarca2 | |
MX2019010040A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
BR112018068412A2 (pt) | composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral | |
CR20220353A (es) | Compuestos y métodos para la degradación dirigida del receptor de andrógenos | |
BR112018011177A2 (pt) | conjugados de citarabina para terapia de câncer | |
WO2018183817A3 (en) | Tumor burden as measured by cell free dna | |
MX2018006531A (es) | Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. | |
CY1121667T1 (el) | Παραγοντες για θεραπεια τριπλα αρνητικου καρκινου μαστου | |
BR112022012867A2 (pt) | Tratamento de câncer com inibidores de cdk12/13 |